Harry J. Wong, MD, MS, DABOM

MIS and Bariatric Surgeon in Southern California | USC Keck | Cedars-Sinai | University of Chicago

[Scott Isaacs @scottisaacsmd]

This study demonstrates that GLP-1 and GLP-1/GIP agonists favorably reshape body composition. The meta-analysis shows significant reductions in fat mass and visceral adipose tissue with relative preservation of lean mass, directly addressing concerns about excessive muscle loss.
https://t.co/bLYG5bZNcq

[Nature Reviews Endocrinology @NatureRevEndo]

New content online: Clinical obesity in Asian people: bridging the gap between adiposity and disease https://t.co/SwM275MTdI

[On The Pen™ @ManOnThePen]

🚨 BREAKING @EliLillyandCo NEWS:

$LLY will release animal study data for at QUINTUPLE AGONIST at #ADA2026

For reference:
Tirzepatide = GLP1/GIP
Retatrutide = GLP1/GIP/Glucagon
New Mol = GLP1/GIP/Glucagon/Amylin/Calcitonin

Early rat studies outperformed retatrutide!

[Dr. Shirin Towfigh @Herniadoc]

On the cover of the Bulletin of @AmCollSurgeons month 🙌

Hernia repair isn’t one-size-fits-all—and personalized surgery matters.

I cover main learning points from our #ACSCC25 Clinical Congress session on “Unique Challenges During Hernia Surgery”.

Read more here:

https://t.co/dgNFuuO047

[Harry J. Wong, MD, MS, DABOM @HWongMD]

@Herniadoc @NovitskyYuri I need to order a copy! 🙌🏼

[NEJM @NEJM]

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @tuftsmedschool and the Maine Medical Center Institute for Research: https://t.co/D0XSLv7U8n

[Avi Roy @agingroy]

16.3% body weight loss. From a daily pill. No injection needed.

@EliLillyandCo's orforglipron just beat oral semaglutide head-to-head in a 1,698-person Phase 3 trial published in @TheLancet. Better blood sugar control. Better weight loss. Taken daily like an aspirin.

Millions of patients qualify for Wegovy or Mounjaro but won't self-inject weekly. Needle anxiety. Supply shortages. Insurance fights. Orforglipron eliminates all three barriers.

The @US_FDA decides in April 2026. If approved, it's the first oral GLP-1 for obesity.

But Lilly isn't alone:
@pfizer: danuglipron (oral, twice-daily)
@Roche: CT-388 (oral, once-daily)
@Amgen: MariTide (monthly injection)
@Viking_VKTX: VK2735 (oral + injectable)

Five companies racing to turn a weekly injection into a morning pill.

[Eric Topol @EricTopol]

The list of conditions for which GLP-1 drugs provide benefit independent of weight loss keeps growing. Add psoriatic arthritis #AAD26 @AADskin

[Michael Mindrum, MD @MichaelMindrum]

Interesting preclinical work on tirzepatide and atherosclerosis. Turns out it shifts macrophages from the pro-inflammatory M1 phenotype toward anti-inflammatory M2, and blunts oxLDL-driven plaque progression. This is separate from weight loss. One more signal that dual GIP/GLP-1 agonism may protect the vasculature directly. https://t.co/i2H8l8Qs5i

[Sully Ayuso @SAyusoMD]

@UTGenSurgery @UTHSCNash_Surg @CUDeptSurg @EndeavorHlth @uchicagosurgres @SAGES_Updates @AmCollSurgeons @DDWMeeting

[Dr. Shirin Towfigh @Herniadoc]

It’s a great general surgery meeting when the first session has #hernias as two of the four talks. 💪

First up is Dr @HWongMD @USCGenSurg and a great presentation by his medical student Sachin Reddi at @KeckMedicineUSC .

Key takeaway: inguinal hernia repair in the obese has its risks, but it seemed interestingly not that bad: 1.5% higher risk of complications with each BMI unit increase from 30kg/m2. That’s a great data point to use when calculating risk in obese patients.

#SCACACS26 @SoCalSurgeons

[Daniel J Drucker @DanielJDrucker]

From #T2D to #obesity #CVD #OSA and now #MASH The expanding benefits of GLP-1 medicines https://t.co/L3C9sbqvaj

[Dr. Shirin Towfigh @Herniadoc]

Voted best hernia post, 2025.

(Credit: @HWongMD )
#itsnotjustahernia

[Beverly G. Tchang, MD @BevTchangMD]

📢 If you're paying attention to body composition changes with #weightloss or #GLP1s, you need to read this article from @GrantTinsleyPhD

⭐️https://t.co/ErYZ04APFq

👉Fat-free mass ≠ Lean mass ≠ lean soft tissue mass ≠ skeletal muscle mass
👉Fat contains fat-free mass
👉DEXA and BIA cannot tell us about skeletal muscle mass

[American College of Surgeons @AmCollSurgeons]

As anti-obesity medications (AOMs) grow in popularity, what does this mean for metabolic and bariatric surgery, the other highly effective weight-loss option? 💉

Experts weigh in on how to combine the two approaches to maximize patient outcomes. https://t.co/s6Z9xBGgZY

[Beverly G. Tchang, MD @BevTchangMD]

I hope @ABOMcert question writers and review courses for the exam are paying attention since this relationship (top panel) has been part of curricula for years

[Beverly G. Tchang, MD @BevTchangMD]

I've been musing on the #biotech race for Most #WeightLoss
Maybe it is motivated by vanity or $, but I consider it a necessary goal

👉We need to create options for people with class 4 #obesity (BMI>50)

Our current #medicines largely cause weight loss by ⬇️food intake and we can only suppress appetite so much. Tirzepatide MIGHT modulate fat metabolism (hand waves): 🐁 https://t.co/93ZeHay54P
https://t.co/4tNTOrx6WA

What we need are more peripherally-acting agents that increase energy utilization from adipocytes

[Michael Albert, MD @MichaelAlbertMD]

🧬 NEW STUDY: Obesity’s Massive Health Impact--from my research group, led by the brilliant @yao_zhiqi.
- - -
🚨 In a nationwide study of 270,000+ adults using the All of Us Research Program, obesity was linked to a higher risk of 16 health conditions—with risk increasing by obesity severity (BMI ≥30).

📊 Top Takeaways
• 42.4% of U.S. adults have obesity; 9.8% have class III (BMI ≥40)
• Class III obesity was linked to:
🔹 11x higher risk of Obstructive Sleep Apnea
🔹 7.7x higher risk of Type 2 Diabetes
🔹 6.7x higher risk of Fatty Liver Disease
🔹 3.5x higher risk of Heart Failure
❤️‍🩹 51.5% of Obstructive Sleep Apnea cases in the population could be attributed to obesity. Similar trends were seen for T2D, gout, and fatty liver disease (MASLD).
💊 As anti-obesity medications like semaglutide and tirzepatide reshape treatment, understanding obesity’s full burden is crucial for prevention and policy.
🔍 This is one of the largest and most diverse obesity studies ever conducted in the U.S., reinforcing obesity as a root cause—not just a risk factor.
📚 Source: https://t.co/Y5a14RJuac
#Obesity #PublicHealth #GLP1 #Semaglutide #ObesityCare #AllOfUs #ChronicDisease #HealthcareInnovation

Thanks to all the collaborators @CiccaroneCenter @MichaelJBlaha @BevTchangMD @rblument1 @khurramn1

[Beverly G. Tchang, MD @BevTchangMD]

Happy to share our post hoc analysis of SURMOUNT trials examining tirzepatide for #obesity based on reproductive stage (pre, peri, post #menopause)

https://t.co/N8XCnVqnLv

👉Menopause was not explicitly captured in the trials but we approximated status with a variety of inputs
👉No difference in #weightloss outcomes based on stage
👉Tirzepatide appears effective for weight loss regardless of stage
👉Clear improvement observed in waist to height ratio compared to placebo

Thank you to @EliLillyandCo for collaboration

[The American Foregut Society @ForegutSociety]

Endoscopy and Antireflux Surgery: A Technical Review of Pre- and Postoperative Evaluation and Recognizing Patterns of Failure.
https://t.co/E7kHGAVjrw

#BetterTogether #AFS2025